In this study, we sought to investigate whether NRF2 activation may constitute a biomarker with prognostic value in T-ALL, able to predict the outcome of the patients; this would be particularly relevant for patients who do not respond to current treatments and for those who relapse and would open new venues for therapeutic intervention. This evidence concerns the gene NFE2L2 and acute lymphoblastic leukemia.